IQM (INTELLIGENT QUALITY MANAGEMENT) ON THE GEM PREMIER 3000, CVP (CALIBRATION VALIDATION PRODUCT)

K022158 · Instrumentation Laboratory CO · CGA · Sep 10, 2002 · Clinical Chemistry

Device Facts

• Record ID: K022158
• Device Name: IQM (INTELLIGENT QUALITY MANAGEMENT) ON THE GEM PREMIER 3000, CVP (CALIBRATION VALIDATION PRODUCT)
• Applicant: Instrumentation Laboratory CO
• Product Code: CGA · Clinical Chemistry
• Decision Date: Sep 10, 2002
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 862.1345
• Device Class: Class 2

Intended Use

The GEM® Premier 3000 is a portable system for use by health care professionals to rapidly analyze whole blood samples that was originally cleared for the U.S. market by K992834, with glucose and lactate parameters added by K010520. Intelligent Quality Management (iQM") is being introduced on the GEM® Premier 3000 as an active quality process control program designed to provide continuous monitoring of the analytical process with real-time, automatic error detection, automatic correction of the system and automatic documentation of all corrective actions, replacing the use of traditional external quality controls. As part of this program, GEM® CVP (Calibration Validation Product) is intended for the external verification of the iQM" cartridge calibration after initial warm-up to ensure its integrity. The reported values for the four levels of GEM® CVP (two levels for pH, blood gases, electrolytes and metabolites; two levels for hematocrit) must meet specifications before the iQM" cartidge can be used for patient sample measurements. Once the cartridge calibration is verified, the internal iOM " program monitors the status of the system during the cartridge use life. To ensure that a total quality management system is adhered to, laboratories should follow local, state and federal regulatory guidelines. As with any analytical device or computer software, there is always the potential for software failure. However, IL conducts rigorous testing and extensive software validation prior to releasing a software revision. If the user encounters a rare software error code, it should be reported to your local IL Technical Support Representative.

Device Story

GEM Premier 3000 is a portable whole blood analyzer. iQM (Intelligent Quality Management) provides continuous, real-time monitoring of the analytical process; replaces traditional external quality controls. System uses GEM CVP (Calibration Validation Product) for initial external verification of cartridge calibration. Once verified, iQM monitors system status during cartridge life; performs automatic error detection, correction, and documentation. Used by healthcare professionals in clinical settings. Output includes analyte values (pH, blood gases, electrolytes, metabolites, hematocrit). Benefits include real-time malfunction detection and reduced reliance on manual external QC. System detects interferences (e.g., Benzalkonium, Thiopental Sodium) and flags failed analytes.

Clinical Evidence

Bench testing only. Precision study (N=135) across 9 instruments evaluated pH, blood gases, electrolytes, metabolites, and hematocrit. Method comparison (N=281-284) against IL Synthesis reference instrument showed high correlation (r=0.9584-0.9988). iQM evaluation analyzed 79 cartridges with QC failures; Failure Pattern Recognition (FPR) detected 74/79 failures (93.7% detection) with zero false positives. Field evaluation (304 samples) demonstrated iQM successfully detected and flagged transient drift/interference (Benzalkonium, Thiopental Sodium) that went undetected by external controls.

Technological Characteristics

Portable whole blood analyzer; uses disposable cartridges. iQM system performs continuous automated monitoring. Connectivity: standalone. Software-based quality control replaces manual external controls. Calibration verified via GEM CVP (4 levels).

Indications for Use

Indicated for use by healthcare professionals for rapid analysis of whole blood samples (pH, blood gases, electrolytes, metabolites, hematocrit) in clinical settings.

Regulatory Classification

Identification

A glucose test system is a device intended to measure glucose quantitatively in blood and other body fluids. Glucose measurements are used in the diagnosis and treatment of carbohydrate metabolism disorders including diabetes mellitus, neonatal hypoglycemia, and idiopathic hypoglycemia, and of pancreatic islet cell carcinoma.

Special Controls

*Classification.* Class II (special controls). The device, when it is solely intended for use as a drink to test glucose tolerance, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9.

Predicate Devices

• ContrIL 9 (K010520)
• GEM critCheck (K992834)

Reference Devices

• IL Synthesis

Submission Summary (Full Text)

{0}------------------------------------------------

### Section 3

## GEM® Premier 3000: Introduction of iQM™ and GEM® CVP 510(k) Summary (Summary of Safety and Effectiveness)

#### Submitted by:

Instrumentation Laboratory Company 113 Hartwell Avenue Lexington, MA 02421 Phone: [phone] Fax:

### Contact Person:

Carol Marble, Regulatory Affairs Manager Phone: [phone] / Fax: [phone]

#### Summary Prepared:

July 1, 2002

### Name of the device:

GEM® Premier 3000: Introduction of iQM™ and GEM® CVP

### Classification name(s):

| 75JJS | Controls for Blood-Gases (Assayed and Unassayed) | |
|----------|--------------------------------------------------|----------|
| 75JJR | Electrolyte Controls (Assayed and Unassayed) | |
| 862.1660 | Quality Control Material (Assayed and Unassayed) | Class I |
| 81GLK | Hematocrit Control | |
| 864.8625 | Hematology Quality Control Mixture | Class II |

### Identification of predicate device(s):

| K010520 | ContrIL ® 9 (FDA cleared as a blood gas/electrolyte/metabolite quality control with the<br>introduction of glucose and lactate on the GEM® Premier 3000) |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------|
| K992834 | GEM® critCheck (FDA cleared as a hematocrit quality control with the introduction of<br>the GEM® Premier 3000) |

### Description of the device/intended use(s):

The GEM® Premier 3000 is a portable system for use by health care professionals to rapidly analyze whole blood samples that was originally cleared for the U.S. market by K992834, with glucose and lactate parameters added by K010520.

Intelligent Quality Management (iQM") is being introduced on the GEM® Premier 3000 as an active quality process control program designed to provide continuous monitoring of the analytical process with real-time, automatic error detection, automatic correction of the system and automatic documentation of all corrective actions, replacing the use of traditional external quality controls.

As part of this program, GEM® CVP (Calibration Validation Product) is intended for the external verification of the iQM" cartridge calibration after initial warm-up to ensure its integrity. The reported values for the four levels of GEM® CVP (two levels for pH, blood gases, electrolytes and metabolites; two levels for hematocrit) must meet specifications before the iQM" cartridge can be used for patient sample measurements. Once the cartridge calibration is verified, the internal iOM "program monitors the status of the system during the cartridge use life.

To ensure that a total quality management system is adhered to, laboratories should follow local, state and federal regulatory guidelines. As with any analytical device or computer software, there is always the potential for software failure. However, IL conducts rigorous testing and extensive software validation prior to releasing a software revision. If the user encounters a rare software error code, it should be reported to your local IL Technical Support Representative.

{1}------------------------------------------------

# Section 3 (Cont.) GEM® Premier 3000: Introduction of iQM™ and GEM® CVP 510(k) Summary (Summary of Safety and Effectiveness)

### Statement of Technological Characteristics of the Device Compared to Predicate Device:

The use of Intelligent Quality Management (iQM") in conjunction with GEM® CVP (Calibration Validation Product) on the GEM® Premier 3000 is not materially different from the use of external controls in performance, safety and effectiveness or intended use.

### Summary of performance data:

### GEM® CVP Precision

A precision study was performed on the GEM® Premier 3000 using the four levels of GEM® CVP (two levels for pH, blood gases, electrolytes and metabolites; two levels for hematocrit). Each level of the verification material was run in singlet once a day for 14 days (twice on Day 1) for a total of 15 replicates on each of 9 different GEM® Premier 3000 instruments (N=135).

| | Parameter | Mean | Day-to-Day<br>%CV (or SD) | Total<br>%CV (or SD) |
|---------------------|------------------|-------|---------------------------|----------------------|
| GEM® CVP<br>Level 1 | pH | 7.200 | 0.005 (SD) | 0.007 (SD) |
| | pCO2 (mmHg) | 70.8 | 1.39 | 1.63 |
| | pO2 (mmHg) | 54.5 | 4.97 | 5.16 |
| | Na+ (mmol/L) | 129.3 | 0.46 | 0.55 |
| | K+ (mmol/L) | 2.90 | 0.25 | 0.70 |
| | Ca++ (mmol/L) | 1.493 | 0.95 | 1.26 |
| | Glucose (mg/dL) | 46.1 | 2.23 | 2.99 |
| | Lactate (mmol/L) | 0.93 | 4.73 | 4.87 |
| GEM® CVP<br>Level 2 | pH | 7.640 | 0.002 (SD) | 0.003 (SD) |
| | pCO2 (mmHg) | 29.9 | 1.78 | 1.91 |
| | pO2 (mmHg) | 148.2 | 1.33 | 1.93 |
| | Na+ (mmol/L) | 158.7 | 0.44 | 0.56 |
| | K+ (mmol/L) | 6.46 | 0.75 | 0.98 |
| | Ca++ (mmol/L) | 0.486 | 1.15 | 2.06 |
| | Glucose (mg/dL) | 192.8 | 1.67 | 1.78 |
| | Lactate (mmol/L) | 5.54 | 1.85 | 2.19 |
| GEM® CVP<br>Level 3 | Hematocrit (%) | 23.4 | 2.14 | 2.11 |
| GEM® CVP<br>Level 4 | Hematocrit (%) | 43.8 | 1.21 | 1.23 |

{2}------------------------------------------------

## Section 3 (Cont.) GEM® Premier 3000: Introduction of iQM™ and GEM® CVP 510(k) Summary (Summary of Safety and Effectiveness)

### Summary of performance data (Cont.):

### GEM® Premier 3000 with iQM™ Method Comparison

In addition, a method comparison study was performed to verify the performance of the GEM® Premier 3000 cartridge with iQM" (Intelligent Quality Management). The method comparison data included arterial, venous, heart bypass and liver transplant blood samples from hospital patients using heparinized syringes. All samples were analyzed on the GEM® Premier 3000 with iQM versus an IL Synthesis as the reference instrument. The GEM® Premier 3000 with iQM " was shown to be statistically similar to the reference instrument:

| Analyte | N | Slope | Intercept | r | Sample Range |
|------------------|-----|--------|-----------|--------|--------------|
| pH | 281 | 1.0802 | -0.5810 | 0.9917 | 7.129-7.559 |
| pCO2 (mmHg) | 282 | 1.0674 | -2.3800 | 0.9839 | 25.3-87.5 |
| pO2 (mmHg) | 282 | 0.9715 | 6.9900 | 0.9988 | 26-489 |
| Na+ (mmol/L) | 271 | 0.9801 | 2.9300 | 0.9584 | 119-148 |
| K+ (mmol/L) | 271 | 0.9743 | -0.0600 | 0.9871 | 3.2-7.4 |
| Ca++ (mmol/L) | 271 | 0.9196 | 0.1270 | 0.9590 | 0.82-1.40 |
| Glucose (mg/dL) | 283 | 1.0111 | 8.8700 | 0.9860 | 66-389 |
| Lactate (mmol/L) | 280 | 0.9323 | 0.1730 | 0.9958 | 0.49-16.67 |
| Hct (%) | 284 | 0.9983 | -0.7999 | 0.9600 | 17-56 |

### iQM™ (Intelligent Quality Management) Evaluation

#### Evaluation of Cartridge Malfunction Detection .

Data from 79 GEM® Premier 3000 cartridges that demonstrated a QC failure during their cartridge use life were extensively analyzed. The Failure Pattern Recognition (FPR) checks were applied to these data to determine if iQM" could detect any malfunction.

The Failure Pattern Recognition (FPR) checks were able to detect malfunction in 74 out of 79 reported QC failures. In most cases, iQM" would have flagged the failure immediately after the sample that caused the malfunction, while with conventional controls, the user would only be aware of a problem when the external control is run again, which may be up to hours after the event occurred. Furthermore, no false positive flags were generated by the FPR checks in any of the 79 investigated cartridges.

### Resolution of 5 Unflagged QC Failures:

For the 5 reported QC failures that iQM" did not detect, there was no identifiable cartridge malfunction. All system parameters were within specifications. There were no error flags and no failure patterns. There were no unusual blood values for the parameter with reported QC failure and the customer did not report any concern about blood results. In all five cases, the reported QC failures were marginal and at one level only. It was concluded that the reported QC failures in these five cartridges could not represent a serious cartridge malfunction. The failures could be considered as a false positive QC failure.

{3}------------------------------------------------

# Section 3 (Cont.) GEM® Premier 3000: Introduction of iQM™ and GEM® CVP 510(k) Summary (Summary of Safety and Effectiveness)

### Field Evaluation: External QC vs. iQM™

During an external field evaluation at a U.S. hospital, a side-by-side comparison was performed on a GEM® Premier 3000 using iQM™ versus two reference instruments, IL Synthesis and GEM® 3000 without iQM using traditional external quality controls. This study was conducted over a 3-week period with the external quality controls run during each day's shift: contrIL" 9 on all three analyzers and GEM® critCheck on the GEM® analyzers only. Each GEM® instrument used a single 450 sample capacity cartridge (1 instrument with and 1 instrument without iQM"). A total number of 304 blood samples were tested.

During this field evaluation, there were no instances of external failure on any instrument. However, the instruments experienced transient drift failures caused by interference as noted below:

- . There were 4 instances of Benzalkonium exposure, which caused analyte failures on all three instruments.
- . There were 8 instances of Thiopental Sodium* exposure, which caused analyte failures on both the GEM® instruments, with and without iQM™.

*NOTE: The IL Synthesis is not affected by Thiopental Sodium.

In all of the above cases, the GEM® Premier 3000 using iQM™ successfully detected and flagged the failed analytes and identified the cause as interference. All three systems self-corrected by the next sample run and therefore, the interference went undetected by external quality controls.

{4}------------------------------------------------

DEPARTMENT OF HEALTH & HUMAN SERVICES

Image /page/4/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" around the perimeter. Inside the circle is an abstract image of an eagle with its wings spread.

Food and Drug Administration 2098 Gaither Road Rockville MD 20850

SEP 1 0 2002

Ms. Carol Marble Regulatory Affairs Manager Instrumentation Laboratory Company 101 Hartwell Avenue Lexington, MA 02421-3125

Re: k022158

> Trade/Device Name: GEM® Premier 3000-iOM™ (Intelligent Ouality Management) AND GEM® CVP (Calibration Validation Product)

Regulation Number: 21 CFR 862.1345 Regulation Name: Glucose test system Regulatory Class: Class II Product Code: CGA; GFS; JJY Dated: July 1, 2002 Received: July 2, 2002

Dear Ms. Marble:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration. Iisting of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

{5}------------------------------------------------

Page 2 -

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and v additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at [phone]. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at [phone]. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers International and Consumer Assistance at its toll-free number [phone] or [phone] or at its internet address "http://www.fda.gov/cdrl/dsma/dsmamain.html".

Sincerely yours,

Steven Butman

Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{6}------------------------------------------------

# Indications for Use Statement

510(k) Number (if known):

Device Name: GEM® Premier 3000 –iQM™ (Intelligent Quality Management) AND GEM® CVP (Calibration Validation Product)

### Indications for Use:

The GEM® Premier 3000 is a portable system for use by health care professionals to rapidly analyze whole blood samples that was originally cleared for the U.S. market by K992834, with glucose and lactate parameters added by K010520.

Intelligent Quality Management (iQM") is being introduced on the GEM® Premier 3000 as an active quality process control program designed to provide continuous monitoring of the analytical process with real-time, automatic error detection, automatic correction of the system and automatic documentation of all corrective actions, replacing the use of traditional external quality controls.

As part of this program, GEM® CVP (Calibration Validation Product) is intended for the external verification of the iQM" cartridge calibration after initial warm-up to ensure its integrity. The reported values for the four levels of GEM® CVP (two levels for pH, blood gases, electrolytes and metabolites; two levels for hematocrit) must meet specifications before the iQM" cartidge can be used for patient sample measurements. Once the cartridge calibration is verified, the internal iOM" program monitors the status of the system during the cartridge use life.

To ensure that a total quality management system is adhered to, laboratories should follow local, state and federal regulatory guidelines. As with any analytical device or computer software, there is always the potential for software failure. However, IL conducts rigorous testing and extensive software validation prior to releasing a software revision. If the user encounters a rare software error code, it should be reported to your local IL Technical Support Representative.

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

| | Jean Cooper |
|-----------------------------------------|-------------|
| (Division Sign-Off) | |
| Division of Clinical Laboratory Devices | |
| 510(k) Number | K022158 |

| Prescription Use (Per 21 CFR 801.019) | X | OR | Over-The-Counter Use |
|---------------------------------------|---|----|----------------------|
|---------------------------------------|---|----|----------------------|

### Section 2

GEM® Premier 3000: iQM™ and GEM® CVP 510(k)